Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 5 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Daewoong Pharmaceutical Co. Ltd. is managing 9 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 5 distinct art units, indicating a range of pharmaceutical subject matter. The portfolio involves 9 distinct examiners, meaning every pending action is assigned to a different individual. This distribution suggests that the applicant must address a variety of examination styles.
The busiest examiner, CHONG, YONG SOO, is responsible for 1 pending office action. Because the workload is spread across many individuals, no single examiner holds a concentration of the cases. Practitioners must navigate the specific preferences of the distinct examiners across the 5 distinct art units involved in these proceedings. Success in the Biotechnology & Pharmaceuticals area will require consistent strategies that can be adapted for the different examiners currently assigned to the cases.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (22%) |
| §112 only | 2 (22%) |
| Double-patenting + other | 3 (33%) |
| Multi-statute (no §101) | 2 (22%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHONG, YONG SOO | 1 | 43.8% | +41.6% |
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
| SCHACHERMEYER, SAMANTHA LYNN | 1 | 36.8% | +72.6% |
| REDWOOD, CHRISTOPHER EVAN | 1 | 0.0% | +0.0% |
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
| ALAM, AYAAN A | 1 | 38.4% | +35.6% |
| KOSAR, ANDREW D | 1 | 42.0% | +31.8% |
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
| CHENG, KAREN | 1 | 76.3% | +26.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577071 | Pharmaceutical Composition for Preventing or Treating Systemic Sclerosis | KOSAR, ANDREW D | 21d |
| 18728531 | METHOD FOR PRODUCING INTERMEDIATE USEFUL FOR SYNETHESIS OF SGLT INHIBITOR | REDWOOD, CHRISTOPHER EVAN | — |
| 18696065 | PHARMACEUTICAL COMPOSITION COMPRISING ENAVOGLIFLOZIN | ALAM, AYAAN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17610303 | PREPARATION FOR PERCUTANEOUS ABSORPTION COMPRISING HIGH DOSE OF DONEPEZIL OR SALT THEREOF | CHENG, KAREN | 79d overdue |
| 18577071 | Pharmaceutical Composition for Preventing or Treating Systemic Sclerosis | KOSAR, ANDREW D | 21d |
| 18560968 | NEW FORMULATION FOR INJECTION COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | SZNAIDMAN, MARCOS L | 26d |
| 18866386 | ARGINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG, YONG SOO | — |
| 18859206 | POTASSIUM-COMPETITIVE ACID BLOCKERS FOR THE TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS | COLEMAN, BRENDA LIBBY | — |
| 18730278 | PHARMACEUTICAL COMPOSITION COMPRISING ENAVOGLIFLOZIN FOR PREVENTING OR TREATING OBESITY IN CANINE ANIMALS | SCHACHERMEYER, SAMANTHA LYNN | — |
| 18718904 | NOVEL ACID ADDITION SALT AND CRYSTALLINE FORM OF (2R, 3S)-2-(3-(4,5-DICHLORO-1H-BENZO[d]IMIDAZOL-1-YL)PROPYL)PIPERIDIN-3-OL | WELLS, LAUREN QUINLAN | — |
| 18696065 | PHARMACEUTICAL COMPOSITION COMPRISING ENAVOGLIFLOZIN | ALAM, AYAAN A | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1611 | 1 |
| 1625 | 1 |
| 1628 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18866386 | ARGINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG, YONG SOO | — | §112 | Non-Final OA | — | Pending | Nov 15, 2024 |
| 18859206 | POTASSIUM-COMPETITIVE ACID BLOCKERS FOR THE TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS | COLEMAN, BRENDA LIBBY | 1629 | §112 | Non-Final OA | — | Pending | Oct 23, 2024 |
| 18730278 | PHARMACEUTICAL COMPOSITION COMPRISING ENAVOGLIFLOZIN FOR PREVENTING OR TREATING OBESITY IN CANINE ANIMALS | SCHACHERMEYER, SAMANTHA LYNN | — | §103 | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18728531 | METHOD FOR PRODUCING INTERMEDIATE USEFUL FOR SYNETHESIS OF SGLT INHIBITOR | REDWOOD, CHRISTOPHER EVAN | — | §102§103§112DP | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18718904 | NOVEL ACID ADDITION SALT AND CRYSTALLINE FORM OF (2R, 3S)-2-(3-(4,5-DICHLORO-1H-BENZO[d]IMIDAZOL-1-YL)PROPYL)PIPERIDIN-3-OL | WELLS, LAUREN QUINLAN | — | §103§112DP | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18696065 | PHARMACEUTICAL COMPOSITION COMPRISING ENAVOGLIFLOZIN | ALAM, AYAAN A | 1611 | §103§112 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18577071 | Pharmaceutical Composition for Preventing or Treating Systemic Sclerosis | KOSAR, ANDREW D | 1625 | §102§103§112Other | Non-Final OA | 21d | Pending | Jan 05, 2024 |
| 18560968 | NEW FORMULATION FOR INJECTION COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | SZNAIDMAN, MARCOS L | 1628 | §103DP | Final Rejection | 26d | Pending | Nov 15, 2023 |
| 17610303 | PREPARATION FOR PERCUTANEOUS ABSORPTION COMPRISING HIGH DOSE OF DONEPEZIL OR SALT THEREOF | CHENG, KAREN | 1623 | §103 | Final Rejection | 79d overdue | Pending | Nov 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial